Cellular Repair & Recovery
BPC-157 / TB-500
Peptide blend
BPC-157 and TB-500 blend
Research context
This preparation combines BPC-157 and TB-500, which act through different reported mechanisms — VEGFR2-associated angiogenic signalling and G-actin sequestration respectively. Each is characterised independently.
Common assays: Component identity by LC-MS · Purity per component · Migration assays
Specification
| Designation | Peptide blend |
|---|---|
| Full name | BPC-157 and TB-500 blend |
| Components | BPC-157 · TB-500 |
| Formats | 10 mL Vial · 15 mL Nasal Spray · 15 mL Oral Spray |
| Solubility | Bacteriostatic water, sterile water |
| Storage | Lyophilised: −20 °C. Reconstituted: 2–8 °C. |
| Current lot | BT1010N0626 → |
Common questions
Do BPC-157 and TB-500 act through the same mechanism?
No. The published literature associates BPC-157 with VEGFR2 and nitric oxide pathway signalling, and TB-500 with G-actin sequestration and cytoskeletal reorganisation.
Same pathway
Related compounds
BPC-157
Body Protection Compound-157
A synthetic pentadecapeptide derived from a gastric juice sequence, studied in migration and angiogenesis models.
TB-500
Thymosin beta-4 fragment
A synthetic fragment corresponding to the actin-binding domain of thymosin beta-4.
KLOW
KLOW
A prepared four-component blend combining repair-signalling and cytokine-pathway compounds.